Drug
Remaxol
Remaxol is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completed
Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
NCT05928286
completed
Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
NCT05789797
completedphase_2
Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis
NCT06183242
completedphase_3
Remaxol® in Malignant Mechanical Jaundice
NCT03416062
Clinical Trials (4)
Showing 4 of 4 trials
NCT05928286
Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
NCT05789797
Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
NCT06183242Phase 2
Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis
NCT03416062Phase 3
Remaxol® in Malignant Mechanical Jaundice
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4